A hemagglutinin-esterase-expressing salmonid alphavirus replicon protects Atlantic salmon (Salmo salar) against infectious salmon anemia (ISA)

Vaccine

Volumn 31, Issue 4, 2013, Pages 661-669

  Wolf, Astrid ^a   Hodneland, Kjartan ^b   Frost, Petter ^b   Braaen, Stine ^a   Rimstad, Espen ^a  

^a NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^b MERCK ANIMAL HEALTH   (United States)

Author keywords

Alphavirus replicon vector; Immunization against ISA; Infectious salmon anemia virus; Reverse genetic system salmonid alphavirus; Salmonid alphavirus based replicon vaccine

Indexed keywords

ESTERASE; HYBRID PROTEIN; INFECTIOUS SALMON ANEMIA VIRUS HEMAGGLUTININ ESTERASE; MATRIX PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS HEMAGGLUTININ; VIRUS VACCINE;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; ATLANTIC SALMON; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; GENE EXPRESSION SYSTEM; GENETIC CODE; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFECTIOUS SALMON ANEMIA; INFECTIOUS SALMON ANEMIA VIRUS; INNATE IMMUNITY; NONHUMAN; ORTHOMYXOVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON;

ANIMALS; AQUACULTURE; FISH DISEASES; HEMAGGLUTININS, VIRAL; ISAVIRUS; ORTHOMYXOVIRIDAE INFECTIONS; REPLICON; SALMO SALAR; VACCINATION; VIRAL FUSION PROTEINS; VIRAL VACCINES;

EID: 84871937355     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.045     Document Type: Article

References (68)

1. Gomez-Casado E., Estepa A., Coll J.M. A comparative review on European-farmed finfish RNA viruses and their vaccines. Vaccine 2011, 29(March (15)):2657-2671.
2. Olsen AB, Hellberg H. Helsesituasjon hos laksefisk. Fiskehelserapporten 2011 Veterinærinstituttet ed. 2012. p. 3-32.
3. Lauscher A., Krossøy B., Frost P., Grove S., Koenig M., Bohlin J., et al. Immune responses in Atlantic salmon (Salmo salar) following protective vaccination against infectious salmon anemia (ISA) and subsequent ISA virus infection. Vaccine 2011, 29(August (37)):6392-6401.
4. Rayner J.O., Dryga S.A., Kamrud K.I. Alphavirus vectors and vaccination. Rev Med Virol 2002, 12(September 5):279-296.
5. Riezebos-Brilman A., de Mare A., Bungener L., Huckriede A., Wilschut J., Daemen T. Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. J Clin Virol 2006, 35(March 3):233-243.
6. Zimmer G. RNA replicons - a new approach for influenza virus immunoprophylaxis. Viruses 2010, 2(2):413-434.
7. Driver D.A., Latham E.M., Polo J.M., Belli B.A., Banks T.A., Chada S., et al. Layered amplification of gene expression with a DNA gene delivery system. Ann NY Acad Sci 1995, 772(November (27)):261-264.
8. Dubensky T.W., Driver D.A., Polo J.M., Belli B.A., Latham E.M., Ibanez C.E., et al. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol 1996, 70(January (1)):508-519.
9. Frolov I., Hoffman T.A., Pragai B.M., Dryga S.A., Huang H.V., Schlesinger S., et al. Alphavirus-based expression vectors: strategies and applications. Proc Natl Acad Sci USA 1996, 93(October (21)):11371-11377.
10. Strauss J.H., Strauss E.G. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 1994, 58(September (3)):491-562.
11. Xiong C., Levis R., Shen P., Schlesinger S., Rice C.M., Huang H.V. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 1989, 243(March (4895)):1188-1191.
12. Hariharan M.J., Driver D.A., Townsend K., Brumm D., Polo J.M., Belli B.A., et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol 1998, 72(February (2)):950-958.
13. Ljungberg K., Whitmore A.C., Fluet M.E., Moran T.P., Shabman R.S., Collier M.L., et al. Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. J Virol 2007, 81(December (24)):13412-13423.
14. Nordstroem E.K., Forsell M.N., Barnfield C., Bonin E., Hanke T., Sundstrom M., et al. Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J Gen Virol 2005, 86(February (Pt 2)):349-354.
15. Davis N.L., Brown K.W., Johnston R.E. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol 1996, 70(June (6)):3781-3787.
16. Kohno A., Emi N., Kasai M., Tanimoto M., Saito H. Semliki forest virus-based DNA expression vector: transient protein production followed by cell death. Gene Ther 1998, 5(March (3)):415-418.
17. Liljestrom P., Garoff H. A new generation of animal cell expression vectors based on the Semliki forest virus replicon. Nat Biotechnol (NY) 1991, 9(December (12)):1356-1361.
18. Schlesinger S., Dubensky T.W. Alphavirus vectors for gene expression and vaccines. Curr Opin Biotechnol 1999, 10(October 5):434-439.
19. Leitner W.W., Ying H., Driver D.A., Dubensky T.W., Restifo N.P. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 2000, 60(January (1)):51-55.
20. Leitner W.W., Bergmann-Leitner E.S., Hwang L.N., Restifo N.P. Type I interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 2006, 24(June (24)):5110-5118.
21. Naeslund T.I., Kostic L., Nordstrom E.K., Chen M., Liljestrom P. Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines. Virol J 2011, 8:36.
22. Biron C.A., Sen G.C. Innate responses to viral infections. Fields virology 2006, 249-278. Lipincott Williams & Wilkins, Philadelphia. 5th edn. D.M. Knipe (Ed.).
23. Leitner W.W., Hwang L.N., deVeer M.J., Zhou A., Silverman R.H., Williams B.R., et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003, 9(January (1)):33-39.
24. Phenix K.V., McKenna B., Fitzpatrick R., Vaughan L., Atkins G., Liljestrom P., et al. Cell culture evaluation of the Semliki forest virus expression system as a novel approach for antigen delivery and expression in fish. Mar Biotechnol (NY) 2000, 2(January (1)):27-37.
25. Karlsen M., Villoing S., Rimstad E., Nylund A. Characterization of untranslated regions of the salmonid alphavirus 3 (SAV3) genome and construction of a SAV3 based replicon. Virol J 2009, 6:173.
26. Karlsen M., Villoing S., Ottem K.F., Rimstad E., Nylund A. Development of infectious cDNA clones of salmonid alphavirus subtype 3. BMC Res Notes 2010, 3(September (1)):241.
27. Moriette C., Leberre M., Lamoureux A., Lai T.L., Bremont M. Recovery of a recombinant salmonid alphavirus fully attenuated and protective for rainbow trout. J Virol 2006, 80(April (8)):4088-4098.
28. Krossøy B., Nilsen F., Falk K., Endresen C., Nylund A. Phylogenetic analysis of infectious salmon anaemia virus isolates from Norway, Canada and Scotland. Dis Aquat Organ 2001, 44(January (1)):1-6.
29. Falk K., Namork E., Dannevig B.H. Characterization and applications of a monoclonal antibody against infectious salmon anaemia virus. Dis Aquat Organ 1998, 34(October (2)):77-85.
30. Aspehaug V., Mikalsen A.B., Snow M., Biering E., Villoing S. Characterization of the infectious salmon anemia virus fusion protein. J Virol 2005, 79(October (19)):12544-12553.
31. Biering E., Falk K., Hoel E., Thevarajan J., Joerink M., Nylund A., et al. Segment 8 encodes a structural protein of infectious salmon anaemia virus (ISAV); the co-linear transcript from segment 7 probably encodes a non-structural or minor structural protein. Dis Aquat Organ 2002, 49(May (2)):117-122.
32. Krossøy B., Devold M., Sanders L., Knappskog P.M., Aspehaug V., Falk K., et al. Cloning and identification of the infectious salmon anaemia virus haemagglutinin. J Gen Virol 2001, 82(July (Pt 7)):1757-1765.
33. Haugland O., Torgersen J., Syed M., Evensen O. Expression profiles of inflammatory and immune-related genes in Atlantic salmon (Salmo salar L.) at early time post vaccination. Vaccine 2005, 23(December (48-49)):5488-5499.
34. Leblanc F., Laflamme M., Gagne N. Genetic markers of the immune response of Atlantic salmon (Salmo salar) to infectious salmon anemia virus (ISAV). Fish Shellfish Immunol 2010, 29(April (3)):217-232.
35. Løvoll M., Austbø L., Jørgensen J.B., Rimstad E., Frost P. Transcription of reference genes used for quantitative RT-PCR in Atlantic salmon is affected by viral infection. Vet Res 2011, 42(January (1)):8.
36. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(December (4)):402-408.
37. Plarre H., Devold M., Snow M., Nylund A. Prevalence of infectious salmon anaemia virus (ISAV) in wild salmonids in western Norway. Dis Aquat Organ 2005 Aug 9, 66(1):71-79.
38. Mikalsen A.B., Sindre H., Torgersen J., Rimstad E. Protective effects of a DNA vaccine expressing the infectious salmon anemia virus hemagglutinin-esterase in Atlantic salmon. Vaccine 2005, 23(September (41)):4895-4905.
39. Agresti A. Categorical data analysis 2002, John Wiley & Sons Inc., Hoboken, NJ, USA.
40. Usage Note 23003: Modeling a binary response and estimating a relative risk (prevalence ratio). http://support.sas.com/kb/23/003.html.
41. McNutt L.A., Wu C., Xue X., Hafner J.P. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003, 157(May 10):940-943.
42. Reddy J.R., Kwang J., Varthakavi V., Lechtenberg K.F., Minocha H.C. Semiliki forest virus vector carrying the bovine viral diarrhea virus NS3 (p80) cDNA induced immune responses in mice and expressed BVDV protein in mammalian cells. Comp Immunol Microbiol Infect Dis 1999, 22(October 4):231-246.
43. McKenna B.M., Fitzpatrick R.M., Phenix K.V., Todd D., Vaughan L.M., Atkins G.J. Formation of infectious pancreatic necrosis virus-like particles following expression of segment A by recombinant Semliki forest virus. Mar Biotechnol (NY) 2001, 3(March (2)):103-110.
44. Chen Z., Sahashi Y., Matsuo K., et al. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 1998, 16(October (16)):1544-1549.
45. Gahlawat S.K., Ellis A.E., Collet B. Expression of interferon and interferon-induced genes in Atlantic salmon Salmo salar cell lines SHK-1 and TO following infection with salmon alphavirus SAV. Fish Shellfish Immunol 2009, 26(April (4)):672-675.
46. Strandskog G., Villoing S., Iliev D.B., Thim H.L., Christie K.E., Jørgensen J.B. Formulations combining CpG containing oliogonucleotides and poly I:C enhance the magnitude of immune responses and protection against pancreas disease in Atlantic salmon. Dev Comp Immunol 2011, 35(November (11)):1116-1127.
47. Sun B., Skjæveland I., Svingerud T., Zou J., Jørgensen J., Robertsen B. Antiviral activity of salmonid gamma interferon against infectious pancreatic necrosis virus and salmonid alphavirus and its dependency on type I interferon. J Virol 2011, 85(September (17)):9188-9198.
48. Kileng Ø., Brundtland M.I., Robertsen B. Infectious salmon anemia virus is a powerful inducer of key genes of the type I interferon system of Atlantic salmon, but is not inhibited by interferon. Fish Shellfish Immunol 2007, 23(August (2)):378-389.
49. Garcia-Rosado E., Markussen T., Kileng Ø., Baekkevold E.S., Robertsen B., Mjaaland S., et al. Molecular and functional characterization of two infectious salmon anaemia virus (ISAV) proteins with type I interferon antagonizing activity. Virus Res 2008, 133(May (2)):228-238.
50. Proietti E., Bracci L., Puzelli S., Pucchino T., Sestili P., De Vincenzi E., et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 2002, 169(July 1):375-383.
51. Tovey M.G., Lallemand C., Meritet J.F., Maury C. Adjuvant activity of interferon alpha: mechanism(s) of action. Vaccine 2006, 24(April (Suppl. 2)):S2-S7.
52. Leitner W.W., Ying H., Restifo N.P. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 1999, 18(December (9-10)):765-777.
53. Leitner W.W., Hwang L.N., Bergmann-Leitner E.S., Finkelstein S.E., Frank S., Restifo N.P. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 2004, 22(March (11-12)):1537-1544.
54. Ying H., Zaks T.Z., Wang R.F., Irvine K.R., Kammula U.S., Marincola F.M., et al. Cancer therapy using a self-replicating RNA vaccine. Nat Med 1999, 5(July (7)):823-827.
55. Koppang E.O., Bjerkas I., Haugarvoll E., Chan E.K., Szabo H.J., Ono N., et al. Vaccination-induced systemic autoimmunity in farmed Atlantic salmon. J Immunol 2008, 181(October (7)):4807-4814.
56. Erdman M.M., Kamrud K.I., Harris D.L., Smith J. Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept. Vaccine 2010, 28(January (3)):594-596.
57. Avogadri F., Merghoub T., Maughan M.F., Hirschhorn-Cymerman D., Morris J., Ritter E., et al. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS ONE 2010, 5(9).
58. Berglund P., Fleeton M.N., Smerdou C., Liljestrom P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 1999, 17(February (5)):497-507.
59. Bernstein D.I., Reap E.A., Katen K., Watson A., Smith K., Norberg P., et al. Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28(December (2)):484-493.
60. Colmenero P., Liljestrom P., Jondal M. Induction of P815 tumor immunity by recombinant Semliki forest virus expressing the P1A gene. Gene Ther 1999, 6(October (10)):1728-1733.
61. Defang G.N., Khetawat D., Broder C.C., Quinnan G.V. Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine 2010, 29(December (2)):212-220.
62. Hubby B., Talarico T., Maughan M., Reap E.A., Berglund P., Kamrud K.I., et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 2007, 25(November (48)):8180-8189.
63. Sun Y., Li H.Y., Tian D.Y., Han Q.Y., Zhang X., Li N., et al. A novel alphavirus replicon-vectored vaccine delivered by adenovirus induces sterile immunity against classical swine fever. Vaccine 2011, 29(October (46)):8364-8372.
64. Yang S.G., Wo J.E., Li M.W., Mi F.F., Yu C.B., Lv G.C., et al. Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1). Vaccine 2009, 27(December (52)):7451-7458.
65. Hetland D.L., Dale O.B., Skjodt K., Press C.M., Falk K. Depletion of CD8 alpha cells from tissues of Atlantic salmon during the early stages of infection with high or low virulent strains of infectious salmon anaemia virus (ISAV). Dev Comp Immunol 2011, 35(February (8)):817-826.
66. Jørgensen S.M., Hetland D.L., Press C.M., Grimholt U., Gjøen T. Effect of early infectious salmon anaemia virus (ISAV) infection on expression of MHC pathway genes and type I and II interferon in Atlantic salmon (Salmo salar L.) tissues. Fish Shellfish Immunol 2007, 23(September (3)):576-588.
67. Jørgensen S.M., Afanasyev S., Krasnov A. Gene expression analyses in Atlantic salmon challenged with infectious salmon anemia virus reveal differences between individuals with early, intermediate and late mortality. BMC Genomics 2008, 9:179.
68. Mjaaland S., Markussen T., Sindre H., Kjøglum S., Dannevig B.H., Larsen S., et al. Susceptibility and immune responses following experimental infection of MHC compatible Atlantic salmon (Salmo salar L.) with different infectious salmon anaemia virus isolates. Arch Virol 2005, 150(November (11)):2195-2216.